
Material Issues for Social Value Creation



Contribute to Healthcare

With the aging of society and the COVID-19 pandemic, the need for health maintenance and disease risk reduction/prevention is expanding around the world. In addition, nucleic acid medicine, gene therapy, and regenerative medicine/cell therapy are also attracting attention as new medical technologies due to the advancement of genome analysis and editing technologies. Sumitomo Chemical will continue to contribute to the improvement of people's quality of life by leveraging the technologies it has cultivated in the pharmaceutical business and other areas.



Basic Policy

We will work at each stage of prevention, diagnosis, and treatment, including the development and dissemination of materials to combat tropical infectious diseases and the ongoing creation of pharmaceutical products in areas of high unmet medical need. In particular, in the area of treatment, we will accelerate the research, development, manufacturing, and marketing of products that contribute to people's health in various fields, with a focus on psychiatry & neurology, oncology, and regenerative medicine/cell therapy.

Initiatives



In addition to our own research, we are introducing cutting-edge technologies in every possible way, including technology introductions and joint research with biotech companies and academia. Using these methods, we strive to develop superior therapeutic drugs and technologies, as well as to cultivate new business areas.

Focus Area

Psychiatry & Neurology

Sumitomo Pharma

Main Products / Compounds under development

- LATUDA[®] (Atypical antipsychotic)
- ulotaront (Atypical antipsychotic)
- (treatment for bipolar I depression)

Oncology

Sumitomo Pharma

Nihon Medi-Physics

Main Products / Compounds under development

- ORGOVYX[®] (Prostate cancer treatment)
- •Theranostics (therapeutic) → P. 80

Regenerative medicine / **Cell therapy**

Sumitomo Chemical Sumitomo Pharma

Compounds under development

- RETHYMIC[®] (allogeneic processed thymus tissue for Pediatric Congenital Athymia)
- CDM0 business in S-RACM0 → P. 80
- Allogeneic iPS cell-derived cell therapy (Parkinson's disease, age-related macular degeneration, etc.)

Diagnosis

We sell diagnostic radiopharmaceuticals for a wide range of diagnostic purposes, including brain, heart, and malignant tumors, and contribute to appropriate diagnosis by physicians.

Main Products / Compounds under development

- Diagnostic radiopharmaceuticals (SPECT diagnostics, PET diagnostics)
- •Theranostics (diagnostics) → P. 80

Others

Sumitomo Chemical Sumitomo Pharma

Main Products / Compounds under development

- MYFEMBREE® (treatment for uterine fibroids, endometriosis)
- GEMTESA[®] (treatment for overactive bladder)
- Active pharmaceutical ingredient (API) production for nucleic acid drugs and high purity gRNA production services for genome editing therapy
- Healthcare solutions using VR and digital devices

We are working to prevent infectious diseases from two main perspectives: strengthening immunity through vaccines and promoting the use of infectious disease prevention materials.

Sumitomo Chemical Sumitomo Pharma

Main Products / Compounds under development

- Olyset Net (malaria prevention)
- Universal Influenza Vaccine
- Malaria Vaccine

* The items in red are already marketed or commercialized, while others are in the development stage. The above includes co-development and joint research projects with other companies (as of the end of July 2022).